Atricure Inc(ATRC) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | RUT | P/E | 282.91 | EPS (ttm) | 0.22 | Insider Own | 3.92% | Shs Outstand | 50.9M | Perf Week | 3.87% |
| Market Cap | 3.12B | Forward P/E | 145.71 | EPS next Y | 287.89% | Insider Trans | -3.99% | Shs Float | 48.9M | Perf Month | 14.29% |
| Enterprise Value | 3.02B | PEG | - | EPS next Q | -0.05 | Inst Own | 104.64% | Short Float | 10% | Perf Quarter | 58.19% |
| Income | 0.01B | P/S | 5.47 | EPS this Y | 145.15% | Inst Trans | 10.99% | Short Ratio | 4.81 | Perf Half Y | 111.06% |
| Sales | 0.57B | P/B | 6.03 | EPS next 5Y | - | ROA | 1.64% | Short Interest | 4.89M | Perf YTD | 54.83% |
| Book/sh | 10.15 | P/C | 18.57 | EPS past 3/5Y | 38.2% 26.83% | ROE | 2.15% | 52W High | -2.78% ($63.00) | Perf Year | 79.67% |
| Cash/sh | 3.3 | P/FCF | 58.66 | Sales past 3/5Y | 17.4% 20.95% | ROIC | 1.8% | 52W Low | 141.52% ($25.36) | Perf 3Y | 82.73% |
| Dividend Est. | - | EV/EBITDA | 86.96 | EPS Y/Y TTM | 128.25% | Gross Margin | 75.77% | Volatility(W/M) | 3.28% 3.85% | Perf 5Y | -18.4% |
| Dividend TTM | - | EV/Sales | 5.31 | Sales Y/Y TTM | 13.94% | Oper. Margin | 2.44% | ATR (14) | 2.13 | Perf 10Y | 246.44% |
| Dividend Ex-Date | - | Quick Ratio | 3.19 | EPS Q/Q | 241.25% | Profit Margin | 1.85% | RSI (14) | 62.93 | Recom | 1.67 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.22 | Sales Q/Q | 12.83% | SMA20 | 6.14% ($57.71) | Beta | 1.25 | Target Price | $58.5 |
| Payout | - | Debt/Eq | 0.14 | Earnings | 2026/11/3 | SMA50 | 10.19% ($55.59) | Rel Volume | 0.95 | Prev Close | $62.48 |
| Employees | 1350 | LT Debt/Eq | 0.14 | EPS/Sales Surpr. | 10688.24% 1.19% | SMA200 | 60.82% ($38.09) | Avg Volume(3M) | 1.02M | Price | $61.25 |
| IPO | 2005/8/5 | Option/Short | Yes/Yes | Trades | 10993 | Volume | 967,304 | Change | -1.97% |
🫀 AtriCure (ATRC) is a US medical device company specializing in surgical treatment for atrial fibrillation (Afib), left atrial appendage management, and post-operative pain management. Focused on surgical ablation, the company supplies its clamp and device product lines to cardiac surgery centers through a direct sales network and distribution partners, building a differentiated position in the niche field of arrhythmia treatment as an innovation-driven medtech company.
Over the past 1 year, on the higher side
3% below its 1-year high.
Traded about as much as usual. That is 95% of its average volume.
Next earnings report: November 3
3 days to go.
ATRC earns at a steady pace
Of every $100 in sales, $2.44 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +145.2% this year.
Tap to view numbers
However, it looks expensive
Counting its debt, for $100 of yearly operating cash you would pay $8,696. Peers typically go for $1,539. Compared with its own 2-year average, it is 376% pricier now.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -18.4%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership is about average
Institutions hold 104.6%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #22 of 51 in the industry
Based on market cap of $3B.
FAQ
What kind of company is ATRC?
ATRC belongs to the Healthcare sector and operates in the Medical Instruments & Supplies industry.
What is the market cap of ATRC?
The market cap of ATRC is approximately $3.1B, ranking 1,725 within its sector.
What is the P/E ratio of ATRC?
ATRC has a P/E ratio of approximately 282.9x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for ATRC?
ATRC has recorded a 52-week high of $63.00 and a low of $25.36.
